Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.
2023 May
Journal Article
Authors:
Sweeney, D.A.;
Tuyishimire, B.;
Ahuja, N.;
Beigel, J.H.;
Beresnev, T.;
Cantos, V.D.;
Castro, J.G.;
Cohen, S.H.;
Cross, K.;
Dodd, L.E.;
Erdmann, N.;
Fung, M.;
Ghazaryan, V.;
George, S.L.;
Grimes, K.A.;
Hynes, N.A.;
Julian, K.G.;
Kandiah, S.;
Kim, H.Jang;
Levine, C.B.;
Lindholm, D.A.;
Lye, D.C.;
Maves, R.C.;
Oh, M.D.;
Paules, C.;
Rapaka, R.R.;
Short, W.R.;
Tomashek, K.M.;
Wolfe, C.R.;
Kalil, A.C.
Secondary:
Open Forum Infect Dis
Volume:
10
Pagination:
ofad205
Issue:
5
PMID:
37206623
URL:
https://pubmed.ncbi.nlm.nih.gov/37206623/
Keywords:
baricitinib; COVID-19; secondary infections
Abstract:
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
